The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, Y.-j.
Right arrow Articles by Shacter, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, Y.-j.
Right arrow Articles by Shacter, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOHEXIMIDE
The Journal of Immunology, 2001, 167: 82-89.
Copyright © 2001 by The American Association of Immunologists

Fas Aggregation Does Not Correlate with Fas-Mediated Apoptosis

Yang-ja Lee1 and Emily Shacter

Laboratory of Immunology, Division of Therapeutic Proteins, Food and Drug Administration, Center for Biologics and Evaluation and Research, Bethesda, MD 20892

Cross-linking of cell surface Fas molecules by Fas ligand or by agonistic anti-Fas Abs induces cell death by apoptosis. We found that a serine protease inhibitor, N-tosyl-L-lysine chloromethyl ketone (TLCK), dramatically enhances Fas-mediated apoptosis in the human T cell line Jurkat and in various B cell lines resistant to Fas-mediated apoptosis. The enhancing effect of TLCK is specific to Fas-induced cell death, with no effect seen on TNF-{alpha} or TNF-related apoptosis-inducing ligand-induced apoptosis. TLCK treatment had no effect on Fas expression levels on the cell surface, and neither promoted death-inducing signaling complex formation nor decreased expression levels of cellular inhibitors of apoptosis (FLICE inhibitory protein, X chromosome-linked inhibitor of apoptosis, and Bcl-2). Activation of the Fas-mediated apoptotic pathway by anti-Fas Ab is accompanied by aggregation of Fas molecules to form oligomers that are stable to boiling in SDS and {beta}-ME. Fas aggregation is often considered to be required for Fas-mediated apoptosis. However, sensitization of cells to Fas-mediated apoptosis by TLCK or other agents (cycloheximide, protein kinase C inhibitors) causes less Fas aggregation during the apoptotic process compared with that in nonsensitized cells. These results show that Fas aggregation and Fas-mediated apoptosis are not directly correlated and may even be inversely correlated.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
Mol. Cancer Ther., November 1, 2009; 8(11): 3088 - 3097.


Home page
 JEMHome page
M. Miyaji, Z.-X. Jin, S. Yamaoka, R. Amakawa, S. Fukuhara, S. B. Sato, T. Kobayashi, N. Domae, T. Mimori, E. T. Bloom, et al.
Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis
J. Exp. Med., July 18, 2005; 202(2): 249 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Ito, T. Nakazato, M. J. Xian, T. Yamada, N. Hozumi, A. Murakami, H. Ohigashi, Y. Ikeda, and M. Kizaki
1'-Acetoxychavicol Acetate Is a Novel Nuclear Factor {kappa}B Inhibitor with Significant Activity against Multiple Myeloma In vitro and In vivo
Cancer Res., May 15, 2005; 65(10): 4417 - 4424.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
F. Henkler, E. Behrle, K. M. Dennehy, A. Wicovsky, N. Peters, C. Warnke, K. Pfizenmaier, and H. Wajant
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability
J. Cell Biol., March 28, 2005; 168(7): 1087 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Xiao, X. Zhang, K. K. Mann, S. Jodo, L. Li, W. N. Jarjour, A. Marshak-Rothstein, D. H. Sherr, and S.-T. Ju
Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells
Int. Immunol., May 1, 2004; 16(5): 759 - 766.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Cheng, M. Kinosaki, M. Takami, Y. Choi, H. Zhang, and R. Murali
Disabling of Receptor Activator of Nuclear Factor-{kappa}B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo
J. Biol. Chem., February 27, 2004; 279(9): 8269 - 8277.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Legembre, M. Beneteau, S. Daburon, J.-F. Moreau, and J.-L. Taupin
Cutting Edge: SDS-Stable Fas Microaggregates: An Early Event of Fas Activation Occurring with Agonistic Anti-Fas Antibody but Not with Fas Ligand
J. Immunol., December 1, 2003; 171(11): 5659 - 5662.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Jaleco, L. Swainson, V. Dardalhon, M. Burjanadze, S. Kinet, and N. Taylor
Homeostasis of Naive and Memory CD4+ T Cells: IL-2 and IL-7 Differentially Regulate the Balance Between Proliferation and Fas-Mediated Apoptosis
J. Immunol., July 1, 2003; 171(1): 61 - 68.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.